Iovance Biotherapeutics
IOVA
218 hedge funds and large institutions have $1.1B invested in Iovance Biotherapeutics in 2022 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 84 increasing their positions, 71 reducing their positions, and 47 closing their positions.
138% more call options, than puts
Call options by funds: $9.1M | Put options by funds: $3.82M
18% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 71
11.9% more ownership
Funds ownership: 97.76% → 109.66% (+12%)
10% less funds holding
Funds holding: 242 → 218 (-24)
25% less capital invested
Capital invested by funds: $1.45B → $1.1B (-$356M)
45% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 47
Top Buyers
| 1 |
MFM
MHR Fund Management
New York
|
+$93.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$37.3M |
| 3 |
Morgan Stanley
New York
|
+$30.6M |
| 4 |
Renaissance Technologies
New York
|
+$18.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$14.5M |
Top Sellers
IOVA Hedge Fund Activity: Q4 2022 in Review
218 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2022, worth a combined $1.1B — down 25% from $1.45B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of IOVA and 26 opened new positions — a net loss of 21 holders — while 71 trimmed existing stakes and 84 added.
The largest buyer was MHR Fund Management, opening a new position worth an estimated $93.7M. The largest seller was Pictet Asset Management (Switzerland), cutting an estimated $27.7M.
- 218 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2022, down from 242 in Q3 2022.
- Funds reported $1.1B of Iovance Biotherapeutics stock for Q4 2022, down 25% quarter-over-quarter.
- 26 funds opened new Iovance Biotherapeutics positions in Q4 2022 and 47 closed out, a net change of -21 holders.
- The largest Iovance Biotherapeutics buyer in Q4 2022 was MHR Fund Management, an estimated $93.7M added.
- The largest Iovance Biotherapeutics seller in Q4 2022 was Pictet Asset Management (Switzerland), an estimated $27.7M sold.
Based on aggregated 13F filings for Q4 2022.